Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced the launch of its SignalStar Multiplex IHC ...
There is a low probability of success for immuno-oncology (IO) research. There is a below average likelihood-of-approval rate for oncology, usually 5.3% vs. 7.9% for all indications. The clinical ...
Please join Leica Biosystems Life Science Field Applications Specialist Mark Lawson for this special event, where Mark shares the development timeline of IHC and multiplex staining on the BOND RX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results